Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
NCT05675930 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
Conditions Studied
Interventions
- DEVICE Photobiomodulation Therapy
- OTHER Placebo sham device
Study Locations (9)
New York
- Memorial Sloan Kettering Cancer Center @ Commack (Consent only) — Commack
- Memorial Sloan Kettering Westchester (Consent only) — Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York
- Memorial Sloan Kettering Cancer Center @ Nassau (Consent only) — Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Consent only) — Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent only) — Middletown
- Memorial Sloan Kettering Cancer Center @ Bergen (Consent only) — Montvale
Maryland
- National Institute of Health (Data Collection AND Specimen Analysis) — Bethesda
Pennsylvania
- University of Pittsburgh Medical Center (Data Collection Only) — Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2026-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05675930
The ClinicalTrials.gov registry entry for NCT05675930 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 2,280 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with GVHD appearing as the primary indexed condition, and to 2 interventions — of which Photobiomodulation Therapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05675930 reports 9 study locations spanning 4 distinct geographic areas — top geographies include New York, New Jersey, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05675930 about?
NCT05675930 is a clinical study titled "A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant". The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
What is the current status of trial NCT05675930?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2022-12-22. Estimated completion is 2026-12-22.
What conditions does trial NCT05675930 study?
This clinical trial studies the following conditions: GVHD, Graft-Versus-Host Disease, Undefined. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05675930?
The interventions under investigation include: Photobiomodulation Therapy (DEVICE), Placebo sham device (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05675930?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 2,280 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05675930 being conducted?
This trial has 9 study locations across Maryland, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.